Tumour refers to a new growth formed by the proliferation of local tissues and cells under the action of various tumorigenic factors, because most of this new growth is a space-occupying protuberance, also known as vegetation. It is found that tumor cells have different metabolic changes from normal cells, and tumor cells can adapt to the changes of metabolic environment through the conversion between glycolysis and oxidative phosphorylation (OXPHOS).

SIR-Spheres Yttrium [90Y] resin microspheres are a heavy anti-tumor drug, which was recently recommended by the National Health Care Professional Organization ("NICE") to treat adult patients with unresectable advanced hepatocellular carcinoma (HCC). It was approved by the US Food and Drug Administration ("FDA") to carry out clinical trials of primary liver cancer (HCC).

SIR-Spheres Yttrium [90Y] resin microspheres are radionuclide products for targeted administration of liver malignant tumors, which is good news for patients with unresectable liver tumors. This product adopts the world-leading interventional technology, injecting SIR-Spheres Yttrium [90Y] resin microspheres into the blood vessels of liver tumors, and releasing high-energy β rays to kill tumor cells. At present, it is the only radioactive microsphere officially approved by FDA in the world.